Wave Life Scienc Stock Price, News & Analysis

Wave Life Sciences (NASDAQ:WVE) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company reported a net loss of $50.5 million with cash and equivalents of $208.5 million, providing runway into 2027.

Key highlights include progress in two main programs: WVE-006 for AATD (alpha-1 antitrypsin deficiency), with multi-dosing complete in first cohort (200mg) and single dosing complete in second cohort (400mg), and WVE-007 for obesity, where dosing is complete in the expanded Cohort 2. The company expects multiple data readouts in H2 2025, including RestorAATion-2 trial data in Q3 2025 and INLIGHT trial data in Q4 2025.

Additionally, Wave is advancing WVE-N531 for DMD with planned NDA filing in 2026, and WVE-003 for Huntington's disease with IND submission expected in H2 2025.

Wave Life Sciences (NASDAQ:WVE), a clinical-stage biotechnology company specializing in RNA medicines, has scheduled its second quarter 2025 financial results conference call for July 30, 2025 at 8:30 a.m. ET. The company will present financial results and provide business updates during the webcast.

Investors and analysts can access the event through the company's investor relations website, with analysts having the option to participate in the Q&A session. An archived version of the webcast will be available after the live event.

Wave Life Sciences presented preclinical data for WVE-007, a GalNAc-siRNA therapy targeting INHBE for obesity treatment, at ADA's Annual Scientific Sessions. The data showed WVE-007's ability to reduce fat while preserving muscle mass, with potential for once or twice yearly dosing. Key findings demonstrated that a single dose led to weight loss comparable to semaglutide, reduced visceral fat, and decreased inflammation in adipose tissue. The therapy showed promise in three scenarios: as monotherapy, in combination with semaglutide (doubling weight loss), and as a maintenance treatment preventing weight rebound after GLP-1 discontinuation. WVE-007's mechanism differs from GLP-1s, targeting fat breakdown through Activin E reduction rather than appetite suppression. The company expects to release first clinical trial data from the INLIGHT study in H2 2025.

Wave Life Sciences (WVE), a clinical-stage biotech company specializing in RNA medicines, has announced its participation in the 2025 Jefferies Global Healthcare Conference. The company's President and CEO, Paul Bolno, MD, MBA, will engage in an analyst-led fireside chat on June 4, 2025, at 4:55 p.m. ET in New York City. The presentation will be accessible via live webcast through the company's investor relations website, with a replay available for a limited time afterward.

Wave Life Sciences (WVE) has appointed Dr. Christopher Wright as Chief Medical Officer. Dr. Wright, who will lead global development including medical, clinical and regulatory functions, brings extensive experience in drug development across multiple therapeutic areas. His background includes leadership roles at Ring Therapeutics, AavantiBio, Cyclerion Therapeutics, and Vertex Pharmaceuticals, where he co-wrote the first approved Breakthrough Status application. Dr. Wright holds an MD and MMSc from Harvard Medical School and a PhD from Vrije University.

As part of his appointment, Dr. Wright received a stock option grant for 300,000 ordinary shares at $5.94 per share, vesting over four years with 25% vesting on May 27, 2026, and the remainder in quarterly installments over three years.

Wave Life Sciences reported Q1 2025 financial results and provided updates across its clinical pipeline. The company ended Q1 with $243.1 million in cash, expecting runway into 2027. Key highlights include: - Completed dosing in first two cohorts of INLIGHT obesity trial for WVE-007, with data expected in 2H 2025 - Advanced RestorAATion-2 trial for WVE-006 in AATD with dosing ongoing; data expected in Q3 and fall 2025 - Reported positive FORWARD-53 trial data for WVE-N531 in DMD, showing significant functional improvements and muscle health benefits - Planning IND submission in 2H 2025 for WVE-003 Phase 2/3 study in Huntington's disease Financial results showed revenue of $9.2M and net loss of $46.9M for Q1 2025. R&D expenses were $40.6M and G&A expenses were $18.4M.

Wave Life Sciences (WVE) has announced it will host a live webcast and conference call on Thursday, May 8, 2025, at 8:30 a.m. ET to discuss its first quarter 2025 financial results and provide business updates. The clinical-stage biotechnology company, which focuses on RNA medicines development, will make the webcast accessible through their investor relations website. Analysts can participate in the Q&A session by dialing (833) 630-1956 for domestic calls or (412) 317-1837 for international calls. An archived version of the webcast will be available on the company's website after the live event.

Wave Life Sciences (WVE) has announced positive 48-week data from its Phase 2 FORWARD-53 trial of WVE-N531, a treatment for Duchenne muscular dystrophy (DMD). The trial demonstrated a statistically significant 3.8-second improvement in Time-to-Rise versus natural history, marking the largest effect observed compared to any approved dystrophin restoration therapy.

Key findings include:

• Dystrophin expression stabilized at 7.8% average, with 88% of boys achieving above 5%
• 28.6% reduction in muscle fibrosis between weeks 24-48
• 50% decline in creatine kinase levels
• Significant improvements in muscle health markers

Following FDA feedback, Wave plans to file a New Drug Application in 2026 for accelerated approval. The company also intends to submit multiple clinical trial applications for other exon skipping programs in 2026, targeting a potential >$2.4 billion market opportunity in the United States.

Wave Life Sciences (WVE) reported its Q4 and full year 2024 financial results, highlighting significant progress across its RNA medicine pipeline. The company ended 2024 with $302.1 million in cash, extending runway into 2027.

Key developments include: dosing initiation in the INLIGHT obesity trial with WVE-007 (data expected 2H 2025); ongoing multi-dosing in RestorAATion-2 trial of WVE-006 for AATD at 200mg; and advancement toward FORWARD-53 48-week DMD data in Q1 2025.

Financial highlights for 2024 include: revenue of $108.3 million (compared to $113.3M in 2023), R&D expenses of $159.7 million (up from $130.0M), and G&A expenses of $59.0 million (increased from $51.3M). The company reported a net loss of $97.0 million for the full year 2024.